Economic evaluation of vaccines in Canada: A systematic review

References

• BIOTECanada Vaccine Industry Committee. Building on the Legacy of Vaccines in Canada: Value, Opportunities, and Challenges Series: Paper 2 – The Current Canadian Vaccine Environment. 2010
   Google Scholar
• Kim J. The role of cost-effectiveness in US vaccination policy. N Engl J Med. 2011 Nov 10; 365(19):1760-1; http://dx.doi.org/10.1056/NEJMp1110539
   PubMed Web of Science ®Google Scholar
• Duclos P. National Immunization Technical Advisory Groups (NITAGs): guidance for their establishment and strengthening. Vaccine 2010; 28(Suppl 1):A18-25; PMID:20412991; http://dx.doi.org/10.1016/j.vaccine.2010.02.027
   PubMed Web of Science ®Google Scholar
• Giesecke J. Modern infectious disease epidemiology. Second edition. London: Arnold, a member of the Hodder Headline group, 2002
   Google Scholar
• Smith JC. The structure, role, and procedures of the US. Advisory Committee on Immunization Practices (ACIP). Vaccine 2010; 28(Suppl 1):A68-75; PMID:20413002; http://dx.doi.org/10.1016/j.vaccine.2010.02.037
   PubMed Web of Science ®Google Scholar
• Hall AJ. The United Kingdom Joint Committee on Vaccination and Immunisation. Vaccine 2010; 28(Suppl 1):A54-7; PMID:20412998; http://dx.doi.org/10.1016/j.vaccine.2010.02.034
   PubMed Web of Science ®Google Scholar
• Nolan TM. The Australian model of immunization advice and vaccine funding. Vaccine 2010; 28(Suppl 1):A76-83; PMID:20413003; http://dx.doi.org/10.1016/j.vaccine.2010.02.038
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the Economic Evaluation of Health Technologies. CADTH; Ottawa:Canada: 2006
   Google Scholar
• Langley JM, Krahn M, Husereau D, Spika J, Fisman DN, Chit A, Van Exan R. Incorporating economic evaluation into immunization decision making in Canada: a workshop. Expert Rev Vaccines 2014 Nov; 13(11):1291-6; http://dx.doi.org/10.1586/14760584.2014.939637
   PubMed Web of Science ®Google Scholar
• Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR. Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices – Modeling Studies. Value Health 2003; 6(1):9-17; PMID:12535234; http://dx.doi.org/10.1046/j.1524-4733.2003.00234.x
   PubMed Web of Science ®Google Scholar
• Berger ML, Mamdani M, Atikns D, Johnson ML. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonradomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report – Part I. Value Health. 2009; 12(8):1044-52; PMID:19793072; http://dx.doi.org/10.1111/j.1524-4733.2009.00600.x
   PubMed Web of Science ®Google Scholar
• Cox E, Martin BC, Van Staa T, Garbe E, Siebert U, Johnson ML. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effect using secondary data sources: the International Society of Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report - Part II. Value Health 2009; 12(8):1053-61; PMID:19744292; http://dx.doi.org/10.1111/j.1524-4733.2009.00601.x
   PubMed Web of Science ®Google Scholar
• Johnson ML, Crown W, Martin BC, Dormuth CR, Siebert U. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part III. Value Health 2009; 12(8):1062-73; PMID:19793071; http://dx.doi.org/10.1111/j.1524-4733.2009.00602.x
   PubMed Web of Science ®Google Scholar
• Pitman R, Fisman D, Zaric GS, Postma M, Kretzschmar M, Edmunds J, Brisson M. Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5. Value Health 2012; 15:828-34; PMID:22999132; http://dx.doi.org/10.1016/j.jval.2012.06.011
   PubMed Web of Science ®Google Scholar
• Briggs A, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel D. Model parameter estimation and uncertainty analysis: A report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group. J Med Decis Making 2012; 32:722-32
   PubMed Web of Science ®Google Scholar
• Drumond M, Brown R, Fendrick MA, Fullerton P, Neumann P, Taylor R, Barbieri M. Use of pharmacoeconomics information—Report of the ISPOR task force on use of pharmacoeconomic/health economic information in health-care decision making. Value Health 2003; 6(4):407-16; PMID:12859580; http://dx.doi.org/10.1046/j.1524-4733.2003.64245.x
   PubMed Web of Science ®Google Scholar
• Drumond M, Barbieri M, Cook J, Glick H, Lis J, Malik F, Reed SD, Rutten F, Sculpher M, Severens J. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health 2009; 12(4):409-18; PMID:19900249; http://dx.doi.org/10.1111/j.1524-4733.2008.00489.x
   PubMed Web of Science ®Google Scholar
• Hay JW, Smeeding J, Carroll NV, Drummond M, Garrision L, Mansely EC, Mullins CD, Mycka JM, Seal B, Shi L. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: The ISPOR drug cost task force report—Part I. Value Health 2010; 13(1):3-7; PMID:19874571; http://dx.doi.org/10.1111/j.1524-4733.2009.00663.x
   PubMed Web of Science ®Google Scholar
• Garrison L, Mansley EC, Abbot TA, Bresnahan B, Hay JW, Smeeding J. Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses:A Societal Perspective: The ISPOR Drug Cost Task Force Report—Part II. Value in Health 2010; 13(1):8-13vvhe_663 3..7; PMID:19883405; http://dx.doi.org/10.1111/j.1524-4733.2009.00660.x
   PubMedGoogle Scholar
• University of Connecticut guide to using the Likert scale. http://www.gifted.uconn.edu/siegle/research/instrument%20reliability%20and%20validity/likert.html. Accessed: 2 December 2013
   Google Scholar
• Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146(4):473-81; PMID:1306034
   PubMed Web of Science ®Google Scholar
• World Health Organization. Cost effectiveness and strategic planning (WHO-CHOICE). World Health Organization 2014. Available at: http://www.who.int/choice/costs/CER_thresholds/en/. Accessed 5 June 2014
   Google Scholar
• World Bank. GDP per capita (current US$). World Development Indicators. Washington, DC, USA. Available at: http://data.worldbank.org/indicator/NY.GDP.PCAP.CD. Accessed 5 June 2014
   Google Scholar
• Ismail SJ, Langley JM, Harris TM, Warshawsky BF, Desai S, FarhangMehr M. Canada's National Advisory Committee on Immunization (NACI): evidence-based decision-making on vaccines and immunization. Vaccine 2010; 28:A58-63; PMID:20412999; http://dx.doi.org/10.1016/j.vaccine.2010.02.035
   PubMed Web of Science ®Google Scholar
• De Wals P, Erickson L. Economic analysis of the 1992–1993 mass immunization campaign against serogroup C meningococcal disease in Quebec. Vaccine 2002; 20(21):2840-4; PMID:12102036; http://dx.doi.org/10.1016/S0264-410X(02)00161-5
   PubMed Web of Science ®Google Scholar
• De Wals P, Erickson LJ, Guay M, Drapeau J, St-Laurent J. Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease. Vaccine 2004; 22(9):1233-40; PMID:15003652; http://dx.doi.org/10.1016/j.vaccine.2003.09.022
   PubMed Web of Science ®Google Scholar
• Krahn MD, John-Baptiste A, Yi Q, Doria A, Remis RS, Ritvo P, Friedman S. Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada. Vaccine 2005; 23(13):1549-58; PMID:15694507; http://dx.doi.org/10.1016/j.vaccine.2004.09.023
   PubMed Web of Science ®Google Scholar
• Bauch CT, Anonychuk AM, Pham BZ, Gilca V, Duval B, Krahn MD. Cost-utility of universal hepatitis A vaccination in Canada. Vaccine 2007; 25(51):8536-48; PMID:17996339; http://dx.doi.org/10.1016/j.vaccine.2007.10.001
   PubMed Web of Science ®Google Scholar
• Brisson M, Van de Velde N, De Wals P, Boily MC. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007; 25(29):5399-408; PMID:17561316; http://dx.doi.org/10.1016/j.vaccine.2007.04.086
   PubMed Web of Science ®Google Scholar
• De Wals P, Coudeville L, Trottier P, Chevat C, Erickson LJ. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis. Vaccine 2007; 25(29):5433-40; PMID:17560695; http://dx.doi.org/10.1016/j.vaccine.2007.04.071
   PubMed Web of Science ®Google Scholar
• Brisson M, Pellissier JM, Camden S, Quach C, De Wals P. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Human Vaccines 2008; 4(3):238-45; PMID:18382137; http://dx.doi.org/10.4161/hv.4.3.5686
   PubMed Web of Science ®Google Scholar
• Debicki D, Ferko N, Demarteau N, Gallivan S, Bauch C, Anonychuk A, Annemans L. Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Vaccine 2008; 26:F16-28; PMID:18992379; http://dx.doi.org/10.1016/j.vaccine.2008.02.040
   PubMed Web of Science ®Google Scholar
• Najafzadeh M, Marra CA, Galanis E, Patrick DM. Cost effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics 2009; 27(12):991-1004; PMID:19908924; http://dx.doi.org/10.2165/11314010-000000000-00000
   PubMed Web of Science ®Google Scholar
• Anonychuk AM, Bauch CT, Merid MF, Van Kriekinge G, Demarteau N. A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. BMC Public Health 2009; 9(1):401; PMID:19878578; http://dx.doi.org/10.1186/1471-2458-9-401
   PubMed Web of Science ®Google Scholar
• Poirier B, De Wals P, Petit G, Erickson LJ, & Pépin J. Cost-effectiveness of a 3-dose pneumococcal conjugate vaccine program in the province of Quebec, Canada. Vaccine 2009; 27(50):7105-09; PMID:19786137; http://dx.doi.org/10.1016/j.vaccine.2009.09.057
   PubMed Web of Science ®Google Scholar
• Sander B, Bauch CT, Fisman D, Fowler RA, Kwong JC, Maetzel A, Krahn M. Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience. Vaccine 2010; 28(38):6210-20; PMID:20643091; http://dx.doi.org/10.1016/j.vaccine.2010.07.010
   PubMed Web of Science ®Google Scholar
• Sander B, Kwong JC, Bauch CT, Maetzel A, McGeer A, Raboud JM, Krahn M. Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis. PLoS Med 2010; 7(4):e1000256; PMID:20386727; http://dx.doi.org/10.1371/journal.pmed.1000256
   PubMedGoogle Scholar
• Chuck AW, Jacobs P, Tyrrell G, Kellner JD. Pharmacoeconomic evaluation of 10-and 13-valent pneumococcal conjugate vaccines. Vaccine 2010; 28(33):5485-90; PMID:20554066; http://dx.doi.org/10.1016/j.vaccine.2010.05.058
   PubMed Web of Science ®Google Scholar
• Wong WW, Woo G, Jenny Heathcote E, Krahn M. Cost effectiveness of screening immigrants for hepatitis B. Liver Int 2011; 31(8):1179-90; PMID:21745300; http://dx.doi.org/10.1111/j.1478-3231.2011.02559.x
   PubMed Web of Science ®Google Scholar
• Tully SP, Anonychuk AM, Sanchez DM, Galvani AP, Bauch CT. Time for change? An economic evaluation of integrated cervical screening and HPV immunization programs in Canada. Vaccine 2012; 30(2):425-35; PMID:22075091; http://dx.doi.org/10.1016/j.vaccine.2011.10.067
   PubMed Web of Science ®Google Scholar
• Fisman DN, Tuite AR. Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada. PloS One 2011; 6(11):e27420; PMID:22110645; http://dx.doi.org/10.1371/journal.pone.0027420
   PubMedGoogle Scholar
• Nosyk B, Sharif B, Sun H, Cooper C, Anis AH, CIHR Canadian HIV Trials Network Influenza Vaccine Research Group.. The cost-effectiveness and value of information of three influenza vaccination dosing strategies for individuals with human immunodeficiency virus 2011
   Google Scholar
• Greer AL, Fisman DN. Use of models to identify cost-effective interventions: pertussis vaccination for pediatric health care workers. Pediatrics 2011; 128(3):e591-9; PMID:21844056
   PubMed Web of Science ®Google Scholar
• Kohli M, Lawrence D, Haig J, Anonychuk A, Demarteau N. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada. BMC Public Health 2012; 12(1):872; PMID:23061913; http://dx.doi.org/10.1186/1471-2458-12-872
   PubMed Web of Science ®Google Scholar
• Fisman DN, Chan CH, Lowcock E, Naus M, Lee V. Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: A model-based evaluation. Vaccine 2012; 30(52):7601-7; PMID:23107595; http://dx.doi.org/10.1016/j.vaccine.2012.10.034
   PubMed Web of Science ®Google Scholar
• Coyle D, Coyle K, Bettinger JA, Halperin SA, Vaudry W, Scheifele DW, Le Saux N. Cost effectiveness of infant vaccination for rotavirus in Canada. Canadian J Infect Dis Medical Microbiol 2012; 23(2):71; PMID:23730312
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Stone PW, Chapman RH, Sandberg EA, Bell CM. The quality of reporting in published cost-utility analyses, 1976–1997. Annals Internal Med 2000; 132(12):964-72; PMID:10858180; http://dx.doi.org/10.7326/0003-4819-132-12-200006200-00007
   PubMed Web of Science ®Google Scholar
• Stone PW, Larson E, Kawar LN. A systematic audit of economic evidence linking nosocomial infections and infection control interventions: 1990-2000. Am J Infect Control 2002; 30(3):145-52; PMID:11988708; http://dx.doi.org/10.1067/mic.2002.121099
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Torrance G, McGuire A. QALYs: The Basics. Value Health 2009; 12(1):S5-9; PMID:19250132; http://dx.doi.org/10.1111/j.1524-4733.2009.00515.x
   PubMedGoogle Scholar
• National Advisory Committee on Immunization. Update on the Invasive Meningococcal Disease and Meningococcal Vaccine Conjugate Recommendations. Can Commun Dis Rep 2009; 36(ACS-3):1-40
   Google Scholar
• National Advisory Committee on Immunization. An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI): Update on the use of herpes zoster vaccine. Public Health Agency Canada January 2014 (Catalogue no. HP40-92/2014E-PDF)
   Google Scholar
• National Advisory Committee on Immunization. Updated statement of the use of rotavirus vaccines. Can Commun Dis Rep 2010:36(ACS-4):1-37
   Google Scholar
• Barbieri M, Drummond MF. Conflict of interest in industry-sponsored economic evaluations: Real or imagined? Curr Oncol Reports 2001; 3(5):410-13; PMID:11489241; http://dx.doi.org/10.1007/s11912-001-0027-2
   PubMedGoogle Scholar